TriSalus Life Sciences to Acquire Fusion Medical for $15M
Ticker: TLSIW · Form: 8-K · Filed: Mar 12, 2024 · CIK: 1826667
| Field | Detail |
|---|---|
| Company | Trisalus Life Sciences, Inc. (TLSIW) |
| Form Type | 8-K |
| Filed Date | Mar 12, 2024 |
| Risk Level | medium |
| Pages | 4 |
| Reading Time | 5 min |
| Key Dollar Amounts | $0.0001, $11.50, $5.7 million, $18.5 million, $11.8 million |
| Sentiment | neutral |
Sentiment: neutral
Topics: acquisition, merger, medical-devices
TL;DR
TriSalus is buying Fusion Medical for $15M, closing Q2 2024.
AI Summary
TriSalus Life Sciences, Inc. announced on March 11, 2024, that it has entered into a definitive agreement to acquire all outstanding equity interests of Fusion Medical, Inc. for an aggregate purchase price of $15 million. The transaction is expected to close in the second quarter of 2024, subject to customary closing conditions.
Why It Matters
This acquisition is expected to expand TriSalus Life Sciences' product portfolio and market reach within the medical device sector.
Risk Assessment
Risk Level: medium — Acquisitions carry inherent risks, including integration challenges and potential overvaluation, which could impact TriSalus Life Sciences' financial performance.
Key Numbers
- $15.0M — Acquisition Price (Aggregate purchase price for Fusion Medical, Inc.)
Key Players & Entities
- TriSalus Life Sciences, Inc. (company) — Acquiring company
- Fusion Medical, Inc. (company) — Acquired company
- $15 million (dollar_amount) — Aggregate purchase price
- March 11, 2024 (date) — Date of definitive agreement
- second quarter of 2024 (date) — Expected closing period
FAQ
What is the primary purpose of this 8-K filing?
This 8-K filing reports on the material event of TriSalus Life Sciences, Inc. entering into a definitive agreement to acquire Fusion Medical, Inc.
What is the name of the company being acquired by TriSalus Life Sciences?
TriSalus Life Sciences, Inc. is acquiring Fusion Medical, Inc.
What is the total purchase price for the acquisition?
The aggregate purchase price for the acquisition of Fusion Medical, Inc. is $15 million.
When is the acquisition expected to be completed?
The acquisition is expected to close in the second quarter of 2024.
What are the conditions for the closing of the acquisition?
The closing of the acquisition is subject to customary closing conditions.
Filing Stats: 1,146 words · 5 min read · ~4 pages · Grade level 13.4 · Accepted 2024-03-11 21:25:17
Key Financial Figures
- $0.0001 — ge on which registered Common Stock, $0.0001 par value per share TLSI Nasdaq Glo
- $11.50 — of Common Stock at an exercise price of $11.50 per share TLSIW Nasdaq Global Marke
- $5.7 million — ystem, are expected to be approximately $5.7 million for the fourth quarter of 2023. This re
- $18.5 million — ects to report revenue of approximately $18.5 million. This represents growth of approximatel
- $11.8 million — h and cash equivalents of approximately $11.8 million as of December 31, 2023. It expects to
Filing Documents
- tm248546d1_8k.htm (8-K) — 33KB
- 0001104659-24-033157.txt ( ) — 249KB
- tlsi-20240311.xsd (EX-101.SCH) — 3KB
- tlsi-20240311_def.xml (EX-101.DEF) — 26KB
- tlsi-20240311_lab.xml (EX-101.LAB) — 36KB
- tlsi-20240311_pre.xml (EX-101.PRE) — 25KB
- tm248546d1_8k_htm.xml (XML) — 5KB
Forward Looking Statements
Forward Looking Statements This Current Report on Form 8-K contains forward-looking statements about the Company and its industry that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this report, including statements regarding the Company's expected financial results for the quarter ended December 31, 2023 and full year ended December 31, 2023, and the Company's projected operating runway into the second quarter of 2024, are all forward-looking statements. In some cases, you can identify forward-looking "would" and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology. The Company has based these forward-looking statements largely on its current expectations and projections about future events and financial trends that the Company believes may affect its financial condition, results of operations, business strategy and financial needs. These forward-looking that the Company's reported financial results will differ from the estimates provided in this Current Report on Form 8-K, the Company's ability to achieve its projected growth or maintain its current levels of revenue, the Company's ability to obtain additional liquidity, the Company's ability to continue as a going concern, and other risk factors described in the Company's filings with the SEC, including the section titled "Risk Factors." See the Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2023, filed with the SEC on November 14, 2023, and other filings made with the SEC for a discussion of important factors that may cause the Company's actual results to differ materially from those expressed or im
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. TRISALUS LIFE SCIENCES, INC. By: /s/ Sean Murphy Seam Murphy Chief Financial Officer Dated: March 11, 2024